Veru (VERU)
(Delayed Data from NSDQ)
$0.78 USD
-0.02 (-2.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.78 0.00 (0.03%) 6:34 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Brokerage Reports
Veru Inc. [VERU]
Reports for Purchase
Showing records 81 - 95 ( 95 total )
Company: Veru Inc.
Industry: Cosmetics
3Q FY2018 Results Reported; Anticipating South Africa Tender and Clinical Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
We are initiating coverage on VERU shares with a BUY rating and 12-18-month price target of $5.00.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Veru Inc.
Industry: Cosmetics
VERU-944 Phase 2 Trial to Start in Summer; Patent Issued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Preclinical Data in Four Types of Cancers to Be Presented at ASCO 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2018 2Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Tamsulosin DRS NDA Filing Fee Waived; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
$10M Non-Dilutive Financing Secured; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2018 1Q Financial Results Reported; NDA Filing On Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Large Public Sector FC2 Orders Expected in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2017 4Q and Full-Year Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Delayed Release Solifenacin for Overactive Bladder In-licensed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Tamsulosin DRS Demonstrates AUC Equivalence; NDA Filing in 1H 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Preboost Co-Promotion Agreement and FC2 Telemedicine Access; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2017 3Q Financial Results Reported; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Veru Inc.
Industry: Cosmetics
FY2017 3Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.